XmAb 564
Alternative Names: IL-2-Fc fusion protein - Xencor; IL2-Fc - Xencor; XmAb-27564; XmAb-564Latest Information Update: 28 Dec 2025
At a glance
- Originator Xencor
- Class Anti-inflammatories; Antipsoriatics; Immunoglobulin Fc fragments; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 2 replacements; Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atopic dermatitis; Autoimmune disorders; Plaque psoriasis
Most Recent Events
- 28 Dec 2025 No recent reports of development identified for phase-I development in Atopic-dermatitis in Canada (SC)
- 28 Dec 2025 No recent reports of development identified for phase-I development in Atopic-dermatitis in USA (SC)
- 28 Dec 2025 No recent reports of development identified for phase-I development in Plaque-psoriasis in Canada (SC)